Printer Friendly

Emphysema drug approved.

Emphysema drug approved

The Food and Drug Administration this week approved the sale of a purified human protein that can slow the progression of emphysema in patients who fail to produce enough of a critical lung-protecting protein. Up to 40,000 people in the United States have a genetic deficiency of the protein, alpha-1 proteinase inhibitor, also known as alpha-1 antitrypsin (SN: 5/2/87, p.277). Of these, perhaps 2,000 suffer noticeable lung damage and would be considered candidates for treatment with the newly approved drug. The protein will not help the vast majority of emphysema patients who have developed the disease from environmental factors such as cigarette smoking.
COPYRIGHT 1987 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1987, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Science News
Date:Dec 12, 1987
Previous Article:Link between earthquakes and El Ninos?
Next Article:SSC: an iffy proposition in Congress.

Related Articles
Mending a torn screen in the lung.
Emphysema drugs may boost lung damage.
Mice smoke out key emphysema enzyme.
Study challenges surgery for lung disease.
Tracheal necrosis and surgical emphysema: a rare complication of thyroidectomy. (Original Article).
Lung surgery aids some emphysema patients. (Breathe Easier).
Cervical emphysema secondary to pneumomediastinum as a complication of childbirth.
A case of recurrent subcutaneous emphysema as a complication of endotracheal intubation.
Surgical emphysema in the neck as a result of a dental procedure.
Spontaneous facial subcutaneous emphysema.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters